ALK-Abello expands in France and introduces new product

Danish allergy immunotherapy specialist ALK-Abello (ALKB: DC) is to invests 18 million euros ($24.8 million) in expansion of production facilities in France, which is the second-largest market in Europe and one that has become increasingly important to ALK.

The expansion will support an increasing demand for ALK´s existing products in France and facilitate the introduction of a new, improved European drop based SLIT product.

The expansion in France will furthermore support the introduction of a new, improved sublingual immunotherapy (SLIT) product called SLIToneULTRA. The new SLIT product upgrades and consolidates ALK’s drop based product portfolio. The product will initially be introduced as a so-called named patient product and is expected to be launched in a series of European countries outside France. SLIToneULTRA will have several distinct improvements over existing therapies and will cover the most relevant allergies. The product is expected to further strengthen ALK’s market position in Europe. The expanded facilities in France will become ALK’s center of excellence for the sublingual product supply, including that of SLIToneULTRA.